e-learning
resources
Amsterdam 2015
Sunday, 27.09.2015
New data on established treatments for asthma and COPD
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Indirect comparison of bronchial thermoplasty (BT) versus omalizumab (OM) for severe uncontrolled asthma
Robert Niven (Manchester, United Kingdom), Robert Niven, Michael Simmonds, Michael Cangelosi, Narinder Shargill, Dominic Tilden, Suzanne Cottrell
Source:
International Congress 2015 – New data on established treatments for asthma and COPD
Session:
New data on established treatments for asthma and COPD
Session type:
Thematic Poster Session
Number:
1020
Disease area:
Airway diseases
Abstract
Objectives:
BT is a one-time treatment recommended as a GINA Step 5 add-on treatment for severe uncontrolled asthma as an alternative to monthly injected biologic OM. No clinical trials have directly compared BT and OM. An indirect treatment comparison (ITC) is presented using optimized asthma therapy (OAT) as a common control. ITCs are often utilised in health technology assessment to establish comparative effectiveness in the absence of direct trial evidence.
Methods:
The ITC comprises a sham-controlled trial of BT (AIR2) and two placebo-controlled trials of OM (INNOVATE; EXTRA), identified in a systematic literature review, and uses Bucher's method.
Results:
Comparing the post-treatment period with BT to ongoing treatment with OM, there were no significant differences in the rate ratios (RRs) for severe exacerbations (RR of BT versus OM via OAT 0.92, p=0.67) or hospitalisations (RR 0.68; p=0.63). The rate of emergency department (ED) visits was reduced by 75% with BT versus OM and was statistically significant (RR 0.25, p=0.01). Improvements in patients' quality of life (response on asthma quality of life questionnaire - AQLQ) were comparable (RR 1.06; p=0.59).
Conclusion:
BT compares favourably to potentially more-costly pharmaceutical therapies for asthma. We observe a significant decrease in Post-treatment ED visits; clinicians evaluating these two add-on treatments should consider the totality of evidence as well as patient preferences to make an informed decision. Due to potential differences of the trial populations and the indirect comparison, the analyses should be interpreted with some caution.
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Robert Niven (Manchester, United Kingdom), Robert Niven, Michael Simmonds, Michael Cangelosi, Narinder Shargill, Dominic Tilden, Suzanne Cottrell. Indirect comparison of bronchial thermoplasty (BT) versus omalizumab (OM) for severe uncontrolled asthma. Eur Respir J 2015; 46: Suppl. 59, 1020
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
The Relationship Between Functional Status and Fatigue After COVID-19 Infection
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Related content which might interest you:
Bronchial thermoplasty in uncontrolled severe persistent asthma. Preliminary results
Source: International Congress 2016 – Airway stenting and ablation
Year: 2016
Short-term effects of bronchial thermoplasty on pulmonary function in patients with severe asthma
Source: International Congress 2016 – Airway stenting and ablation
Year: 2016
Effect of different inhalation methods on the airway clearance in moderate and severe AECOPD
Source: International Congress 2016 – Pharmacological management of COPD
Year: 2016
Bronchial thermoplasty for asthma
Source: Eur Respir Mon; 2010: 48: 228–236
Year: 2010
Monitoring of airway resistance (Raw) in exacerbation of asthma
Source: Annual Congress 2013 –Monitoring lung function in airway diseases
Year: 2013
Cost-effectiveness of bronchial thermoplasty (BT) treatment relative to no BT treatment option for patients with severe asthma
Source: International Congress 2014 – Asthma and COPD devices and treatments
Year: 2014
Efficacy of bronchial thermoplasty (BT) in patients with severe asthma: the AIR2 trial
Source: Annual Congress 2009 - Persistent asthma: still an uncontrolled disease requiring new treatments strategies in 2009
Year: 2009
Changes in symptoms, respiratory function, airway inflammation, and airway hyperresponsiveness over 10 year of inhaled corticosteroid therapy in adult asthma patients
Source: International Congress 2015 – New data on established treatments for asthma and COPD
Year: 2015
Improved effects of aerosol-type fluticasone propionate/formoterol combination on residual asthmatic inflammation in distal airways of patients with moderate asthma
Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments
Year: 2014
Atomization inhalation on the NO content in the airway of patients with bronchial asthma
Source: International Congress 2016 – The wide spectrum of respiratory nursing research and practice: across all ages and diseases
Year: 2016
Improved effects of formoterol-budesonide combination on residual eosinophilic inflammation in asthmatic peripheral airway
Source: Annual Congress 2013 –Asthma drugs: new findings
Year: 2013
Reduction of airway smooth muscle mass in airway biopsies following bronchial thermoplasty; the TASMA randomized controlled trial
Source: International Congress 2016 – Advancements in bronchoscopy
Year: 2016
Montelukast improves air trapping, not airway remodeling, in moderate-to-severe patients with asthma: A pilot tudy
Source: Annual Congress 2013 –Asthma and COPD drugs: efficacy, safety and pharmacoeconomics
Year: 2013
Long-term effects of bronchial thermoplasty on airway smooth muscle and collagen deposition in severe asthma
Source: International Congress 2016 – Asthma: from basic mechanisms to novel therapeutic perspectives
Year: 2016
Corticosteroid insensitivity in airway smooth muscle cells of severe asthma and COPD: Modulation by IFN-γ
Source: Annual Congress 2012 - Basic and translational studies in COPD
Year: 2012
Comparison of inspiratory flow rates using an innovative dry powder inhaler (DPI) in patients with mild–severe asthma and severe COPD
Source: International Congress 2014 – Rationale behind respiratory drug development
Year: 2014
Audit of bronchial thermoplasty patients who did not complete their treatment session as planned
Source: International Congress 2016 – Asthma management
Year: 2016
Clinical response of severe asthma patients following Bronchial Thermoplasty.
Source: International Congress 2017 – To freeze or heat?
Year: 2017
Influence of basic therapy of bronchial asthma (BA) on respiratory symptoms in patients with pulmonary TB associated with bronchial asthma
Source: International Congress 2014 – Tuberculosis: from epidemiology to therapy 1
Year: 2014
Long-term asthma treatment guided by airway hyperresponsiveness in children: a randomised controlled trial
Source: Eur Respir J 2007; 30: 457-466
Year: 2007
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept